Xencor Inc
XNCRHealthcare|Biotechnology|USA
$15.86
-0.27 (-1.64%)
Tangible Book
$6.86
Clinical Trials (34)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05297903 XmAb20717 in Advanced Biliary Tract Cancers | Biliary Tract Cancer | P2 | Active | 27 | Open-label | XmAb20717 |
| NCT06619990 Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis | Ulcerative Colitis (UC) | P1P2 | Recruiting | 270 | RCT, Double-blind | XmAb942, Placebo |
| NCT05032040 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Ovarian Cancer, Clear Cell Carcinoma | P2 | Active | 170 | Open-label | vudalimab |
| NCT07284797 A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases | Healthy, Idiopathic Inflammatory Myopathies | P1 | Recruiting | 60 | Open-label | XmAb657 |
| NCT06276491 Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Ovarian Cancer, Endometrial Cancer | P1 | Recruiting | 282 | Open-label | XmAb541 |
| NCT05433142 Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | P1 | Recruiting | 307 | Open-label | XmAb819 |
| NCT07230353 A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Recruiting | 68 | Open-label | Plamotamab |
| NCT05879185 A Study of XmAb23104 in People With Sarcoma | Sarcoma | P2 | Terminated | 6 | Open-label | XmAb23104 |
| NCT02725476 Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) | IgG4-RD | P2 | Completed | 20 | Open-label | XmAb5871 |
| NCT05328102 Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) | Diffuse Large-cell B-cell Lymphoma | P2 | Terminated | 3 | RCT, Open-label | Plamotamab, Tafasitamab, Lenalidomide |
| NCT06173505 Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Nonsquamous Non-small Cell Lung Cancer | P1P2 | Terminated | 28 | RCT, Open-label | — |
| NCT05005728 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | P2 | Completed | 72 | Open-label | vudalimab monotherapy |
| NCT02725515 A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P2 | Completed | 105 | RCT, Double-blind | XmAb5871, Placebo to match XmAb5871 |
| NCT04590781 Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | Merkel Cell Carcinoma, Small Cell Lung Cancer | P1P2 | Terminated | 4 | Open-label | XmAb18087, XmAb18087 ± Pembrolizumab |
| NCT05900648 Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | Colorectal Cancer, Colon Cancer | P2 | Withdrawn | — | Open-label | Regorafenib, XmAb20717 |
| NCT01161511 Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P1 | Completed | 27 | Open-label | XmAb5574 |
| NCT02730312 PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia | P1 | Completed | 120 | Open-label | XmAb14045 |
| NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma | P1 | Completed | 198 | RCT, Open-label | XmAb®23104, Yervoy® (ipilimumab) |
| NCT05733351 Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | P1 | Terminated | 4 | Open-label | Abiraterone, Docetaxel, Enzalutamide, Vudalimab |
| NCT03411915 A Study of XmAb®18087 in Subjects With NET and GIST | Neuroendocrine Tumor, Gastrointestinal Neoplasm | P1 | Completed | 62 | Open-label | XmAb18087 |
| NCT04857866 Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers | Safety in Healthy Volunteers | P1 | Completed | 48 | RCT, Double-blind | XmAb27564, Placebo |
| NCT05996445 A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors | Solid Tumors | P1 | Terminated | 7 | Open-label | XmAb662, Keytruda® (pembrolizumab) |
| NCT02148744 Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis | Allergic Rhinitis, Allergic Conjunctivitis | P1 | Completed | 72 | RCT, Double-blind | XmAb7195, Placebo |
| NCT03445663 Study Evaluating AMG 424 in Subjects With Multiple Myeloma | Relapsed/ Refractory Multiple Myeloma | P1 | Terminated | 27 | Open-label | AMG 424 |
| NCT07593092 Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors | Ovarian Cancer | P1 | Not Yet Recruiting | 90 | Open-label | XmAb541, XmAb808 |
| NCT05695898 XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy | Metastatic Melanoma, Advanced Melanoma | P1 | Terminated | 6 | Open-label | XmAb22841, XmAb23104 |
| NCT03849469 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | Melanoma, Cervical Carcinoma | P1 | Completed | 78 | Open-label | XmAb®22841, Pembrolizumab (Keytruda®) |
| NCT05585034 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma | P1 | Completed | 60 | Open-label | XmAb®808, Keytruda® (pembrolizumab) |
| NCT02881853 Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 | Healthy Volunteers, Atopic Disease | P1 | Completed | 57 | RCT, Open-label | XmAb7195, Placebo |
| NCT02867098 XmAb5871 Bioavailability Study | Healthy Volunteers | P1 | Completed | 50 | Open-label | XmAb5871 |
| NCT03517488 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | Melanoma, Breast Carcinoma | P1 | Completed | 150 | Open-label | XmAb20717 |
| NCT06005792 Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis | Psoriasis, Atopic Dermatitis | P1 | Terminated | 23 | RCT, Double-blind | XmAb27564, Placebo |
| NCT02924402 Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies | B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | P1 | Completed | 154 | Open-label | XmAb13676 |
| NCT00606645 Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma | Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma | P1 | Completed | 23 | Open-label | XmAb2513 |